Vivek Subbiah, MD, joined SCRI in 2023, and serves as Chief, Early-Phase Drug Development. In his role, Dr. Subbiah oversees SCRI’s nine drug development units and leads the expansion of early-phase capabilities and programs across SCRI’s growing research network. Dr. Subbiah also serves as a treating physician at SCRI Oncology Partners, where he attends to patients and provides them with the opportunity to participate in state-of-the-art cutting-edge clinical trials. Dr.Subbiah comes to SCRI from the University of Texas MD Anderson Cancer Center where he was an Associate Professor in the Department of Investigational Cancer Therapeutics. During his near 15-year tenure there, Dr. Subbiah held several leadership roles.
Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the US FDA, European Medicines Agency, and other agencies across the world. He has authored over 400 peer-reviewed publications in several high-impact journals. He is also a recipient of numerous awards. After finishing his medical education in India, Dr. Vivek completed a combined Residency program in Internal medicine and Pediatrics at Case Western Reserve University. He received board-certifications in both internal medicine/pediatrics/fellowships in both Adult and Pediatric oncology at MD Anderson.